gefitinib has been researched along with bibw 2992 in 221 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bibw 2992) | Trials (bibw 2992) | Recent Studies (post-2010) (bibw 2992) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,044 | 147 | 1,007 |
| Protein | Taxonomy | gefitinib (IC50) | bibw 2992 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0361 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0168 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.037 | |
| Cytochrome P450 2E1 | Homo sapiens (human) | 0.014 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.037 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0007 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.037 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (1.36) | 29.6817 |
| 2010's | 156 (70.59) | 24.3611 |
| 2020's | 62 (28.05) | 2.80 |
| Authors | Studies |
|---|---|
| Alberti, JG; Alligood, KJ; Caferro, TR; Chamberlain, SD; Dickerson, SH; Dickson, HD; Emerson, HK; Gerding, RM; Griffin, RJ; Hubbard, RD; Keith, BR; Mullin, RJ; Petrov, KG; Reno, MJ; Rheault, TR; Rusnak, DW; Sammond, DM; Smith, SC; Stevens, KL; Uehling, DE; Waterson, AG; Wood, ER | 1 |
| Chao, YS; Chen, CH; Chittimalla, SK; Chu, CY; Coumar, MS; Fang, MY; Ho, YL; Hsieh, HP; Hsu, JT; Huang, CT; Leou, JS; Liao, CC; Lien, TW; Lin, CW; Lin, WH; Peng, YH; Reddy, R; Shiao, HY; Song, JS; Wu, JS; Wu, SH; Wu, SY | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Ji, P; Li, LL; Lin, XD; Liu, JJ; Wang, LJ; Wang, WJ; Wei, YQ; Xu, Y; Yang, J; Yang, SY; Zhang, CH; Zheng, RL; Zhong, L | 1 |
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Anderton, M; Ashton, S; Ballard, P; Bethel, PA; Box, MR; Bradbury, RH; Brown, SJ; Butterworth, S; Campbell, A; Chorley, C; Colclough, N; Cross, DA; Currie, GS; Finlay, MR; Grist, M; Hassall, L; Hill, GB; James, D; James, M; Kemmitt, P; Klinowska, T; Lamont, G; Lamont, SG; Martin, N; McFarland, HL; Mellor, MJ; Orme, JP; Perkins, D; Perkins, P; Richmond, G; Smith, P; Ward, RA; Waring, MJ; Wells, S; Whittaker, D; Wrigley, GL | 1 |
| Chen, W; Deng, H; Han, J; Huang, W; Li, B; Li, P; Li, Y; Liu, Y; Ma, C; Miao, H; Qi, W; Shao, J; Shen, J; Sun, X; Xia, G; Xiang, Z; Xu, J; Yu, Y; Zhang, J; Zhang, L; Zhang, Y | 1 |
| Chen, K; Cheng, Z; Johnström, P; Li, DY; Varnäs, K; Wang, J; Yang, ZF; Zeng, Q; Zhang, X | 1 |
| Döring, E; Engel, J; Günther, M; Juchum, M; Keul, M; Lategahn, J; Laufer, S; Rauh, D; Tumbrink, HL | 1 |
| Baumann, M; Becker, C; Engel, J; Goebel, L; Günther, G; Hengstler, JG; Hennes, E; Keul, M; Lategahn, J; Müller, H; Rauh, D; Schultz-Fademrecht, C; Smith, S; Tumbrink, HL; Unger, A | 1 |
| Chen, ZS; Korlipara, V; Lei, Z; Romu, AA; Zhou, B | 1 |
| Fukuda, T; Ishibashi, F; Iwao, M; Nishiya, N; Oku, Y; Tokushima, K; Uehara, Y; Umeki, T; Xiang, G; Yoshida, Y | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Hou, W; Ma, Y; Ren, Y; Sun, H; Yan, B; Zhang, Z | 1 |
| Jang, S; Jung, D; Lee, JW; Lee, S; Min, KH; Song, J | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Das, D; Hong, J | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
| Basetti, V; Keesara, M; Maiti, P; Mansour, TS; Moghudula, AG; Pallepati, RR; Potluri, V | 1 |
| Abouzid, KAM; Chen, CS; Dokla, EME; Fang, CS | 1 |
| Chang Hsu, Y; Chen, CH; Chen, CP; Chen, CT; Chen, PY; Chu, CY; Hsieh, HP; Hsu, TA; Ke, YY; Kuo, FM; Lien, TW; Lin, SY; Lin, WH; Peng, YH; Shiao, HY; Sun, HY; Wang, SY; Wu, SY; Yeh, KC; Yeh, TK | 1 |
| Chen, Y; Cheng, Z; Huang, X; Jiang, Y; Qiao, H; Xie, J; Yang, L; Yu, B; Zhao, W; Zhou, W | 1 |
| Ding, K; Lu, X; Smaill, JB | 1 |
| Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM | 1 |
| Bauer, S; Baumann, M; Becker, C; Grabe, T; Hardick, J; Hodson, L; Jeyakumar, K; Ketzer, J; Keul, M; Kirschner, T; Klövekorn, P; Lategahn, J; Müller, MP; Niggenaber, J; Rauh, D; Terheyden, S; Tumbrink, HL; Unger, A; van Otterlo, WAL; Weisner, J | 1 |
| An, B; Chen, C; Fan, R; Li, J; Li, X; Song, X; Wei, S; Zhang, Q; Zou, Y | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
| Aziz, MW; Elgendy, AA; Kamal, AM; Mohamed, KO | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Fukuoka, M; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Takezawa, K; Tanizaki, J; Yamaguchi, H | 1 |
| Crinò, L; Metro, G | 1 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Dziadziuszko, R; Jassem, J | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Couraud, S | 1 |
| Honda, Y; Ichihara, E; Kiura, K; Kubo, T; Kudo, K; Minami, D; Murakami, T; Ninomiya, T; Ochi, N; Takigawa, N; Tanimoto, M | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Noor, A; Teugels, E; Umelo, IA | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Köhler, J; Schuler, M | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Nakanishi, Y | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Ardizzoni, A; Artioli, F; Bersanelli, M; Lucchi, L; Tiseo, M | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Fang, W; Hong, S; Hu, Z; Kang, S; Liang, W; Qin, T; Sheng, J; Wu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Jenks, S | 1 |
| Boeck, S; Bruns, CJ; Camaj, P; Gamba, S; Giessen, C; Haertl, C; Heinemann, V; Laubender, RP; Modest, DP; Stintzing, S; Wang, Y; Zhao, Y | 1 |
| Reguart, N; Remon, J | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chen, X; Huang, H; Ma, S; Wang, B; Wu, K; Zhang, S; Zheng, X | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Bierbach, U; Day, CS; Gueble, MJ; Kucera, GL; Pickard, AJ; Qiao, X; Yang, M | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Chung, C | 1 |
| Chang, H; Chen, G; Chen, Y; Ding, J; Huang, R; Ji, D; Song, B; Yuan, L | 1 |
| Azzoli, CG | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K | 1 |
| Syed, YY | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Arvis, CD; Boyer, M; Hirsh, V; Kim, DW; Kim, M; Kim, SW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, KH; Lu, S; Massey, D; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shahidi, M; Shi, Y; Tan, EH; Tsai, CM; Yang, JC; Zazulina, V; Zhang, L | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW | 1 |
| Fujimoto, J; Goshima, N; Higa, A; Hiyama, G; Hoshi, H; Inageda, K; Ishikawa, K; Kawamura, Y; Semba, K; Takagi, M; Takahashi, N; Togashi, T; Wakamatsu, A; Watanabe, S | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Song, Y; Yuan, DM | 1 |
| Akashi, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Obara, T; Ogata, H; Okamoto, I; Yoshimoto, G | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Boyer, M; Dodd, N; Fan, J; Hirsh, V; Kim, DW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, DH; Lee, KH; Lu, S; Märten, A; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shi, Y; Tan, EH; Yang, JC; Zhang, L | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Bosch-Barrera, J; Costa, EC; Insa, A; Isla, D; Kraemer, S; Lee, C; Majem, M; Moran, T; Palmero, R; Provencio, M; Puig, M; Reguart, N; Rosell, R; Schnell, D | 1 |
| Gandara, DR; Melosky, B; Popat, S | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Beretta, GD; Caprioli, A; Ceresoli, GL; Codignola, C; Fraccon, AP; Meriggi, F; Ogliosi, C; Prochilo, T; Scartozzi, M; Zaniboni, A | 1 |
| Bennouna, J; Chouaid, C; de Pouvourville, G; Do, P; LeLay, K; Luciani, L; Moro-Sibilot, D; Perol, M; Vergnenègre, A | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Kodama, K; Maniwa, T; Takeda, M; Yamamoto, Y | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K | 1 |
| Girard, N | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Furukawa, R; Matsumoto, Y; Ohara, S; Taniguchi, Y; Usui, K | 1 |
| Ho, CC; Hsiue, EH; Lee, JH; Liao, WY; Lin, CC; Shih, JY; Wu, TH; Yang, JC; Yu, CJ | 1 |
| Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P | 1 |
| Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K | 1 |
| Li, Y; Liu, Y; Ou, Q; Shao, YW; Wang, X; Wu, X; Ying, J | 1 |
| Barrios, CH; Boyer, M; Chih-Hsin Yang, J; Geater, SL; Hirsh, V; Kato, T; Lee, KH; Märten, A; Mok, T; O'Byrne, K; Orlov, S; Park, K; Paz-Ares, L; Peil, B; Schuler, M; Sequist, LV; Tan, EH; Tsai, CM; Wu, YL; Yamamoto, N; Zhang, L | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Choi, MK; Kim, JH; Kim, SW; Kim, YC; Lee, JS; Oh, IJ; Park, K | 1 |
| Fujita, N; Inase, N; Katayama, R; Nishio, M; Uchibori, K | 1 |
| Chang, CL; Chang, JH; Chang, YC; Chow, JM; Hsu, HL; Lin, WC; Wu, ATH; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Beck, TN; Boumber, Y; Dulaimi, E; Kharin, LV; Kit, OI | 1 |
| Aguiar, PN; de Lima Lopes, G; Del Giglio, A; Haaland, B; Park, W; San Tan, P | 1 |
| Ahn, JS; Ahn, MJ; Kim, Y; Lee, SH; Park, K; Sun, JM | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Aigner, P; Barbacid, M; Brcic, L; Casanova, E; Dezso, K; Dome, B; Eferl, R; Grabner, B; Győrffy, B; Hidalgo, M; Hruschka, N; Laszlo, V; Lopez-Casas, PP; Mohrherr, J; Moldvay, J; Moll, HP; Moriggl, R; Musteanu, M; Penninger, J; Popper, H; Pranz, K; Schramek, D; Sibilia, M; Stiedl, P; Stoiber, D | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I | 1 |
| Chihara, Y; Hasegawa, I; Hiranuma, O; Hiraoka, N; Kaneko, Y; Kubota, Y; Shiotsu, S; Takayama, K; Takeda, T; Takumi, C; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, A | 1 |
| Ge, W; Li, X; Wang, H; Wang, Y; Zeng, C | 1 |
| Chan, KK; Chew, DS; Ezeife, DA; Kirk, V; Le, LW; Lee, R; Leighl, NB; Nixon, NA | 1 |
| Beretta, GD; Bonomi, M; Cerchiaro, E; Ceresoli, GL; D'Argento, E; Di Noia, V; Finocchiaro, G; Rossi, S; Santoro, A; Toschi, L | 1 |
| Chen, JS; Chen, KY; Ho, CC; Hsu, CL; Lee, JH; Liao, WY; Lin, YT; Lin, ZZ; Shih, JY; Yang, CY; Yang, JC; Yu, CJ | 1 |
| Chu, YB; Gu, X; Kuo, D; Su, B; Wu, B; Zhang, Q; Zhang, YJ; Zhao, YY | 1 |
| Arvis, CD; Boyer, M; Hirsh, V; Kim, DW; Kim, SW; Kölbeck, K; Laskin, J; Lee, KH; Lu, S; Märten, A; Massey, D; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Schuler, M; Shi, Y; Tan, EH; Yang, JC; Zhang, L | 1 |
| Baretta, Z; Basso, M; Bernardi, D; Bonanno, L; Bonetti, A; Bortolami, A; Calvetti, L; Conte, P; Corte, DD; Favaretto, A; Frega, S; Gatti, C; Giovanis, P; Gori, S; Guarneri, V; Menis, J; Oliani, C; Oniga, F; Palazzolo, G; Pasello, G; Redelotti, R; Rosetti, F; Santo, A; Toso, S; Vicario, G; Zustovich, F | 1 |
| Endo, M; Gon, Y; Harada, H; Kawamura, T; Kenmotsu, H; Kobayashi, H; Mamesaya, N; Mitsuya, K; Miyawaki, E; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nakasu, Y; Omori, S; Ono, A; Takahashi, T; Wakuda, K | 1 |
| Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J | 1 |
| Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Jung, HA; Kim, Y; Lee, K; Lee, SH; Park, K; Sun, JM | 1 |
| Baba, K; Hasegawa, Y; Ishioka, Y; Itoga, M; Nakagawa, H; Okudera, K; Sakamoto, H; Shiratori, T; Taima, K; Takanashi, S; Tanaka, H; Tasaka, S; Tsuchiya, J; Yasugahira, H | 1 |
| Chooback, N; Ho, C; Lau, SC; Melosky, B | 1 |
| Ehrnrooth, E; Ellis, SH; Feng, J; Hirsh, V; Lee, KH; Lu, S; Märten, A; Park, K; Paz-Ares, L; Samuelsen, CH; Schuler, M; Sequist, LV; Tang, W; Wu, YL; Yang, JC; Zhou, C | 1 |
| Hamamoto, J; Ikemura, S; Kawada, I; Kobayashi, K; Manabe, T; Masuzawa, K; Naoki, K; Oashi, A; Soejima, K; Tani, T; Terai, H; Yasuda, H | 1 |
| Atagi, S; Hirashima, T; Imamura, F; Inoue, T; Kimura, M; Kuhara, H; Kumagai, T; Kunimasa, K; Moriizumi, K; Nakahama, K; Nishino, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y | 1 |
| Chang, LC; Chang, LY; Chen, KY; Lim, CK; Shih, JY; Yu, CJ | 1 |
| Hanafi, A; Jayusman, M; Sutandyo, N | 1 |
| Bonanno, L; Buoro, V; Calabrese, F; Cecere, FL; Conte, P; Dal Maso, A; Del Conte, A; Frega, S; Indraccolo, S; Lorenzi, M; Macerelli, M; Monteverdi, S; Nardo, G; Pasello, G; Pilotto, S; Polo, V; Roca, E; Scattolin, D; Urso, L; Zulato, E | 1 |
| Chen, CY; Chen, YF; Chen, YH; Shih, JY; Yu, CJ | 1 |
| Beretta, GD; Bonomi, M; Cerchiaro, E; Ceresoli, GL; D'Argento, E; Finocchiaro, G; Franceschini, D; Navarria, P; Noia, VD; Rose, F; Rossi, S; Santoro, A; Scorsetti, M; Toschi, L | 1 |
| DerSarkissian, M; Duh, MS; Fernandes, AW; Laliberté, F; Pavilack, M; Subramanian, J | 1 |
| Chella, A; Crucitta, S; Danesi, R; Del Re, M; Garassino, MC; Gianfilippo, G; Mazzoni, F; Miccoli, M; Petrini, I; Pozzessere, D; Restante, G; Rofi, E; Valleggi, S | 1 |
| Chen, YH; Chien, LN; Fang, WT; Hsieh, YY; Lo, YW | 1 |
| Antonio Casado, J; Arango, D; Bueren, JA; Carrascoso-Rubio, C; Carreras-Puigvert, J; González, A; Helleday, T; Lasa, A; Lerma, E; Martínez-Barriocanal, Á; Minguillón, J; Montanuy, H; Nieto, R; Ramírez, MJ; Riera, P; Rovirosa, L; Surrallés, J | 1 |
| Chen, H; Huang, J; Luo, Z; Meng, L; Sun, S; Yang, B | 1 |
| Hsu, JC; Lai, WW; Su, WC; Wang, JD; Yang, SC | 1 |
| Chen, KH; Tseng, LC; Wang, CL; Weng, LC | 1 |
| Damhuis, RAM; Gijtenbeek, RGP; Groen, HJM; van der Wekken, AJ; van Geffen, WH | 1 |
| Abe, T; Asada, K; Hataji, O; Hayai, S; Hida, T; Imaizumi, K; Inui, N; Ito, K; Karayama, M; Kimura, T; Kubo, A; Kunii, E; Morikawa, S; Murotani, K; Okuno, M; Oya, Y; Shindoh, J; Suda, T; Takahashi, K; Taniguchi, H; Tsuda, T; Yamagichi, T; Yoshida, T | 1 |
| Arrieta, O; Barrón, F; Catalán, R; de la Garza, J; Flores-Estrada, D; Guzmán-Vazquez, S; Lara-Mejía, L; Ramos-Ramírez, M; Soto-Molina, H | 1 |
| Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC | 1 |
| Joseph, AM; Kamath, A; Mittal, S; Rajala, MS | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hayashi, S; Hayashihara, K; Hizawa, N; Ichimura, H; Iguchi, K; Inagaki, M; Inage, Y; Ishikawa, H; Kaburagi, T; Kamiyama, K; Kikuchi, N; Kiyoshima, M; Kodama, T; Kurishima, K; Miyazaki, K; Nakamura, H; Nakamura, R; Nomura, A; Okubo, H; Saito, K; Saito, T; Sakai, M; Sato, Y; Satoh, H; Sekine, I; Shiozawa, T; Suzuki, H; Tamura, T; Yamada, H; Yamada, Y; Yamamoto, Y; Yamashita, T | 1 |
| Lin, N; Lu, S; Ma, Z; Wang, Y; Zhang, S; Zhou, H | 1 |
| Mohty, R; Tfayli, A | 1 |
| Eisenstein, M | 1 |
| Li, G; Lin, Z; Mei, J; Xu, X | 1 |
| Akdeniz, N; Akinci, MB; Aktas, BY; Alan, O; Avci, O; Ayhan, M; Basoglu, T; Bilgin, B; Celik, E; Cinkir, HY; Dede, DS; Demir, A; Demirkazık, A; Deniz, GI; Dogan, I; Erol, C; Gulmez, A; Gurbuz, M; Hizal, M; Ilhan, A; Karaagac, M; Karatas, F; Kilickap, S; Koca, S; Kut, E; Menevse, S; Oksuzoglu, B; Ozyukseler, DT; Paydas, S; Sakalar, T; Sen, E; Sendur, MAN; Taskaynatan, H; Tatli, AM; Yalcin, B; Yucel, S; Yumuk, F | 1 |
| Ando, K; Kishino, Y; Kusumoto, S; Manabe, R; Ohmori, T; Sagara, H; Yamaoka, T | 1 |
| Gupta, A; Momi, G; Vaid, AK | 1 |
| Cai, Y; He, MF; Jiang, LL; Li, CY; Wei, P; Zhang, SR; Zhang, Y | 1 |
| Au, JS; Au, KH; Cho, WCS; Kwan, CK; Li, YC; Ming, WK; You, JHS | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Chen, HH; Fearon, D; Horton, S; Kim, YJ; McFarlane, T; Oremus, M | 1 |
| Choi, H; Kho, BG; Kim, MS; Kim, YC; Lee, JK; Oh, HJ; Oh, IJ; Park, CK | 1 |
| Barinova, M; Bratova, M; Cernovska, M; Coupkova, H; Dolezal, D; Fischer, O; Hrnciarik, M; Hurdalkova, K; Koubkova, L; Krejci, J; Porzer, B; Skrickova, J; Svaton, M; Tuzova, T; Zemanova, M | 1 |
| Fujita, A; Hatsuyama, T; Inotsume, N; Mukai, Y; Sato, H; Toda, T; Wakamoto, A; Yoshida, T | 1 |
| Chang, GC; Chen, JJW; Chen, KC; Chin, CS; Hsu, KH; Huang, YH; Su, KY; Tseng, JS; Yang, TY; Yu, SL | 1 |
| Bae, JA; Chung, IJ; Ha, HH; Kang, H; Kim, H; Kim, KK; Kim, N; Kim, SJ; Ko, YS; Moon, KS; Oh, IJ; Rho, JK | 1 |
| Chang, CC; Chen, YY; Huang, WL; Lai, WW; Tseng, YL; Yen, YT | 1 |
| Aguilar-Serra, J; Cortijo, J; Gimeno-Ballester, V; Milara, J; Pastor-Clerigues, A; Trigo-Vicente, C | 1 |
| Chen, R; Xia, X; Yang, X; Yu, Z; Zhang, M; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Chang, HC; Chang, YP; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Endo, M; Harada, H; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Miyawaki, E; Miyawaki, T; Mori, K; Murakami, H; Naito, T; Nishioka, N; Omori, S; Ono, A; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Dai, JG; Gao, DC; Hou, B; Liu, QX; Lu, X; Zheng, H; Zhou, D | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Choowongkomon, K; Mahalapbutr, P; Poo-Arporn, RP; Rungrotmongkol, T; Todsaporn, D | 1 |
| Cortiula, F; Corvaja, C; De Maglio, G; Fasola, G; Pelizzari, G | 1 |
| Aerts, JGJV; Dingemans, AC; Hurkmans, DP; Mathijssen, RHJ; Oomen-de Hoop, E; Paats, MS; van der Leest, CH; van Leeuwen, RW; van Thiel, ERE; Veerman, GDM | 1 |
| Li, J; Peng, L; Stebbing, J; Zhu, L | 1 |
| Igai, H; Kamiyoshihara, M; Matsuura, N; Numajiri, K; Ohsawa, F | 1 |
| Abbie, E; Boyne, DJ; Brenner, DR; Cheung, WY; Eaton, K; Elia-Pacitti, J; Ewara, EM; Gogna, P; Hu, LXY; Jarada, TN; O'Sullivan, DE; Pabani, A; Rose, JB; Yusuf, A | 1 |
| Boily, G; Boulanger, J; Golo, KT; Guédon, AC; Lehuédé, C; Qureshi, S; Roussafi, F; Strumpf, E; Truchon, C | 1 |
| Chang, CF; Chang, JW; Fang, YF; Hsu, PC; Huang, CY; Kuo, CS; Wu, CE; Yang, CT | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Lee, SH; Park, S; Sun, JM | 1 |
| Chen, KY; Ho, CC; Hsu, CL; Huang, CT; Liao, WY; Lin, CA; Su, TJ; Tsai, TH; Yang, CY; Yu, CJ | 1 |
| Chen, GY; Chen, KY; Liang, SK; Wei, YF; Weng, TI | 1 |
| Chen, M; Li, D; Li, H; Li, M; Shi, P; Yang, T | 1 |
| Cheng, C; Dong, J; Wang, S; Wang, Z; Yu, D; Zhang, S | 1 |
| Chang, HC; Chang, YP; Chen, YC; Chen, YM; Chuang, HY; Huang, KT; Lai, CH; Tseng, CC; Wang, CC | 1 |
| Chang, HC; Chang, YP; Chen, YM; Chuang, HY; Fang, WF; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Arffman, M; Iivanainen, S; Kaarteenaho, R; Koivunen, JP; Manninen, O; Puuniemi, L | 1 |
| Chiu, TH; Chung, FT; Fang, YF; Guo, YK; Hsu, PC; Huang, AC; Huang, CH; Ju, JS; Ko, HW; Kuo, CS; Tung, PH; Wang, CC; Yang, CT | 1 |
46 review(s) available for gefitinib and bibw 2992
| Article | Year |
|---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors | 2020 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Proportional Hazards Models; Quinazolines | 2014 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines | 2017 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction | 2019 |
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Injury; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2021 |
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Topics: Acrylamides; Administration, Oral; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Randomized Controlled Trials as Topic | 2021 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Treatment Outcome | 2021 |
The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Prospective Studies; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2023 |
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
18 trial(s) available for gefitinib and bibw 2992
| Article | Year |
|---|---|
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Progression-Free Survival | 2018 |
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; United States | 2018 |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors | 2019 |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Dosage Calculations; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Survival Analysis; Treatment Outcome | 2019 |
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors | 2020 |
Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
Topics: Afatinib; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; ErbB Receptors; Erlotinib Hydrochloride; Esomeprazole; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors | 2022 |
157 other study(ies) available for gefitinib and bibw 2992
| Article | Year |
|---|---|
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ErbB Receptors; Mice; Pharmacokinetics; Pyrimidines; Pyrrolidines; Receptor, ErbB-2; Structure-Activity Relationship | 2009 |
Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
Topics: Antineoplastic Agents; Aurora Kinases; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; ErbB Receptors; Furans; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Models, Molecular; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Spectrometry, Mass, Fast Atom Bombardment | 2010 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
Topics: Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Immunohistochemistry; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2012 |
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Mice; Middle Aged; Mutation; Protein Kinase Inhibitors; Rats, Inbred Strains; Xenograft Model Antitumor Assays | 2014 |
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Humans; Lung Neoplasms; Mice, Inbred BALB C; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2014 |
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Topics: Animals; Brain; Brain Neoplasms; Central Nervous System; Clinical Trials, Phase I as Topic; Dogs; Drug Discovery; ErbB Receptors; Macaca fascicularis; Male; Mice; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Xenograft Model Antitumor Assays | 2015 |
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2017 |
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2017 |
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
Topics: Acrylamides; Animals; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mutagenesis, Site-Directed; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2017 |
Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
Topics: Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Click Chemistry; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.
Topics: Exons; Humans; Mutation; Protein Kinase Inhibitors; Thioctic Acid | 2019 |
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Oxadiazoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Structure-Activity Relationship | 2019 |
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Mice, Inbred ICR; Mice, Nude; Mutation; Protein Kinase Inhibitors; Pyrimidines; Rats; Receptor, ErbB-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Conformation; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2020 |
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles | 2020 |
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.
Topics: Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Kinetics; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinazolinones; Structure-Activity Relationship | 2021 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mice; Mutation; Oxonic Acid; Pemetrexed; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2013 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Exons; Female; Gefitinib; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Topics: Afatinib; Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorometry; Gefitinib; Humans; Indoles; Microscopy, Fluorescence; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectrophotometry; Sulfonamides | 2013 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Renal Dialysis | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; ErbB Receptors; Exons; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Mutation; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3 | 2015 |
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Topics: Afatinib; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors.
Topics: Afatinib; Cell Line; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Dose-Response Relationship, Drug; Gefitinib; Gold; Humans; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Thiourea | 2015 |
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Topics: 6-Aminonicotinamide; Afatinib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Glucose; Humans; Metabolome; Multiple Myeloma; Oxygen; Pentose Phosphate Pathway; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; ras Proteins; Receptor, ErbB-2; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2016 |
therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2016 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
Topics: Afatinib; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Transfection | 2017 |
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topics: Afatinib; Agranulocytosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.
Topics: Afatinib; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Drug Resistance; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Neutrophils; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins | 2017 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Nivolumab; Prognosis | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors | 2018 |
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril | 2018 |
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence | 2018 |
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2018 |
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Republic of Korea; Treatment Outcome; Young Adult | 2018 |
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Cell Transformation, Neoplastic; Cells, Cultured; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors | 2018 |
Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors | 2018 |
Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged | 2018 |
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
Afatinib restrains K-RAS-driven lung tumorigenesis.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Quinazolines; Research Design | 2018 |
Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Clinical Decision-Making; Cost-Benefit Analysis; ErbB Receptors; Exons; Gefitinib; Health Care Costs; Humans; Lung Neoplasms; Markov Chains; Middle Aged; Models, Biological; Models, Economic; Mutation; Progression-Free Survival; Quality-Adjusted Life Years; Survival Analysis | 2019 |
Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Topics: Acrylamides; Afatinib; Aniline Compounds; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years | 2018 |
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sex Factors; Taiwan; Time Factors | 2019 |
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Models, Econometric; Pemetrexed; Quality-Adjusted Life Years; Survival Analysis | 2019 |
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Critical Pathways; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Guideline Adherence; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Mutation; Practice Guidelines as Topic; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Failure | 2019 |
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Cranial Irradiation; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2019 |
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2019 |
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation Rate | 2019 |
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Survival Analysis | 2019 |
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
Topics: Afatinib; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Multimerization; Treatment Outcome | 2019 |
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Topics: Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population].
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2019 |
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; France; Gefitinib; Humans; Liquid Biopsy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation | 2020 |
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sequence Deletion | 2019 |
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Radiofrequency Ablation; Retrospective Studies | 2019 |
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Health Resources; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; United States | 2019 |
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Taiwan; Treatment Outcome; Young Adult | 2020 |
Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Fanconi Anemia; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Topics: Acrylamides; Adverse Drug Reaction Reporting Systems; Afatinib; Aniline Compounds; Data Mining; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pharmacovigilance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Safety; United States; United States Food and Drug Administration | 2020 |
Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Male; Propensity Score; Protein Kinase Inhibitors; Quality of Life; Survival Rate; Taiwan; Tertiary Care Centers | 2020 |
Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Correlation of Data; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Skin; Surveys and Questionnaires; Taiwan | 2020 |
Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Netherlands; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Male; Middle Aged; Mutation; Protein Kinase Inhibitors | 2020 |
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2020 |
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure | 2020 |
PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Movement; Cell Proliferation; ErbB Receptors; Estrenes; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Phosphodiesterase Inhibitors; Phospholipase C gamma; Protein Kinase Inhibitors; Pyrrolidinones; Recombinant Proteins; Signal Transduction | 2020 |
Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Brain; Cells, Cultured; Endothelial Cells; Gefitinib; Humans; Indoles; Intracellular Space; Limit of Detection; Linear Models; Protein Kinase Inhibitors; Quinolines; Reproducibility of Results | 2021 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolinones | 2021 |
New lung-cancer drugs extend survival times.
Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis | 2020 |
Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Male; Metformin; Middle Aged; Mutation; Protein Kinase Inhibitors | 2021 |
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2021 |
Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib.
Topics: Afatinib; Animals; Animals, Genetically Modified; Chemical and Drug Induced Liver Injury; Embryo, Nonmammalian; Gefitinib; Gene Expression Regulation; Liver; Protein Kinase Inhibitors; Zebrafish | 2021 |
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hong Kong; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Retrospective Studies | 2021 |
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Ontario; Protein Kinase Inhibitors | 2021 |
Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors | 2021 |
Real-life Effectiveness of Afatinib
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Czech Republic; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carbazoles; Chromatography, Liquid; Crizotinib; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolinones; Sulfones; Tandem Mass Spectrometry | 2021 |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
New strategy for suppressing the growth of lung cancer cells harboring mutations in the ATP-binding region of EGFR by targeting the molecular motor MYO1D.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; ErbB Receptors; Gefitinib; In Vitro Techniques; Lung Neoplasms; Mice; Mutation; Myosins | 2021 |
Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs.
Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Surgical Procedures; Salvage Therapy | 2021 |
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
Topics: Afatinib; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
Topics: Acrylamides; Afatinib; Aged; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Confidence Intervals; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2021 |
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Drug Therapy; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Topics: Acrylamides; Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Failure | 2021 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.
Topics: Afatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Heat-Shock Proteins; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrimidines | 2022 |
Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor].
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Nivolumab; Pemetrexed; Survivors | 2022 |
Prevalence, Treatment Patterns, and Outcomes of Individuals with
Topics: Afatinib; Alberta; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Platinum; Prevalence | 2022 |
Advanced Lung Cancer Patients' Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quebec | 2022 |
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Taiwan; Tyrosine Kinase Inhibitors | 2023 |
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Topics: Afatinib; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
Effects of targeted lung cancer drugs on cardiomyocytes studied by atomic force microscopy.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Microscopy, Atomic Force; Myocytes, Cardiac; Protein Kinase Inhibitors | 2023 |
Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2023 |